Status:
COMPLETED
Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis
Lead Sponsor:
Keesler Air Force Base Medical Center
Conditions:
Subacromial Bursitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To date no trials have been performed looking at whether or not intra-bursal injection of an IL-1 antagonist provides pain relief similar to that of a corticosteroid injection. The subcutaneous inject...
Detailed Description
Background: Subacromial bursitis is an inflammatory condition which is typically triggered by altered rotator cuff mechanics. One of the mainstays of therapy is corticosteroid injection. Given the inf...
Eligibility Criteria
Inclusion
- At least 18 years of age or older and at a minimum have a recent history (more than 3 days worth) of shoulder pain with moderate to severe tenderness to palpation over the subacromial bursa.
Exclusion
- Allergies to lidocaine, marcaine, or kenalog.
- Allergies to rilonacept
- Flare of active inflammatory arthritis (such as a flare of Rheumatoid Arthritis)
- Gout or Pseudogout attack of the shoulder with subacromial tenderness
- Active infection
- Actively receiving chemotherapy, radiation therapy, or anticipating surgery for neoplasia
- Active myocardial infarction
- Clinical and/or radiographic evidence of a fracture (clavicular, humeral, or other).
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT01830699
Start Date
March 1 2013
End Date
March 1 2014
Last Update
August 4 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keesler Medical Center
Keesler Air Force Base, Mississippi, United States, 39534